Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

@article{Kaminski1996Iodine131antiB1RF,
  title={Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.},
  author={Mark S. Kaminski and Kenneth R. Zasadny and Issac R Francis and Matthias Fenner and Charles W. Ross and Adam Milik and Judith Estes and Melissa K Tuck and Denise D Regan and Susan Fisher and Stephan Glenn and Richard L. Wahl},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1996},
  volume={14 7},
  pages={1974-81}
}
PURPOSE The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies. We conducted a phase I dose-escalation trial to assess the toxicity, tumor targeting, and efficacy of nonmyeloablative doses of an anti-CD20 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma who had failed chemotherapy. PATIENTS AND METHODS Patients were first given tracelabeled doses… CONTINUE READING
107 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 107 extracted citations

Similar Papers

Loading similar papers…